A 58-year-old woman with established coronary artery disease and prior MI is on atorvastatin 80 mg daily. Her LDL-C is 85 mg/dL (goal <70 mg/dL for secondary prevention). She has no statin intolerance. Triglycerides are 280 mg/dL and HDL-C is 38 mg/dL. What is the most appropriate next step?

## Management of Residual LDL-C Gap in Secondary Prevention **Key Point:** In a patient with established CAD and prior MI already on maximally tolerated statin therapy (atorvastatin 80 mg), the **primary target** is LDL-C reduction to <70 mg/dL. When LDL-C remains above goal, the next step is to add a PCSK9 inhibitor (e.g., evolocumab), which provides the most potent additional LDL-C lowering with proven cardiovascular outcome benefit. ### Clinical Context This patient has: - **LDL-C:** 85 mg/dL — **15 mg/dL above the secondary prevention goal of <70 mg/dL** (primary unmet target) - **Triglycerides:** 280 mg/dL (elevated, but not at the threshold [≥500 mg/dL] where pancreatitis risk mandates urgent fibrate therapy) - **HDL-C:** 38 mg/dL (low, but no proven CV outcome benefit from pharmacologically raising HDL-C) - **Established CAD with prior MI** — very high-risk patient requiring aggressive LDL-C lowering ### Why PCSK9 Inhibitor (Evolocumab)? **Mechanism:** - Monoclonal antibody that inhibits PCSK9, preventing LDL receptor degradation → ↑ LDL receptor recycling → ↓ LDL-C by **50–60%** - Proven CV outcome benefit: FOURIER trial (evolocumab) demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease on statin therapy **Guideline support (ACC/AHA 2018, ESC/EAS 2019):** > In very high-risk patients (established ASCVD) on maximally tolerated statin therapy who do not achieve LDL-C goal, **add ezetimibe first**, and if still not at goal, **add a PCSK9 inhibitor** (Class I, Level A recommendation). **High-Yield:** The LDL-C gap is the primary therapeutic target in secondary prevention. Fibrates reduce triglycerides and raise HDL-C but have **not demonstrated** a reduction in MACE in large outcome trials (ACCORD-Lipid, FIELD) when added to statin therapy. PCSK9 inhibitors have robust outcome data. *(Harrison's Principles of Internal Medicine, 21e, Ch. 400; KD Tripathi 8e Ch. 31)* ### Why Not the Other Options? | Option | Reason Incorrect | |--------|-----------------| | **A) Fenofibrate** | Addresses TG/HDL but does NOT lower LDL-C sufficiently; no proven MACE reduction on top of statins; TG of 280 mg/dL does not mandate urgent fibrate use | | **B) Atorvastatin 120 mg** | Maximum approved dose is **80 mg**; increasing beyond this is not permissible | | **C) Bempedoic acid** | Lowers LDL-C ~18% and uric acid, but is a second-line agent; PCSK9 inhibitor is preferred for this degree of LDL-C gap in very high-risk patients; bempedoic acid does not lower uric acid — it actually **raises** uric acid (a known adverse effect), making option C factually misleading | ### Treatment Sequencing in Secondary Prevention ``` Maximally tolerated statin (atorvastatin 80 mg) ↓ LDL-C still above goal Add ezetimibe (if not already on it) ↓ LDL-C still above goal Add PCSK9 inhibitor (evolocumab / alirocumab) ← This patient's next step ``` **Clinical Pearl:** In very high-risk ASCVD patients, every 1 mmol/L (~39 mg/dL) reduction in LDL-C reduces MACE by ~22% (CTT meta-analysis). Prioritizing LDL-C lowering with a PCSK9 inhibitor is the evidence-based next step before addressing residual triglyceride risk.